In preclinical studies, FGF21 lowered plasma insulin, triglycerides, liver fat,and body weight [6], which led to high expectations for a novel, efficacious treatment for obesity, type 2 diabetes, dyslipidemia, and MASH [7]. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.